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‡Author for correspondenceThe rat b -tropomyosin (TM) gene expresses two isoforms
via alternative RNA splicing, namely skeletal muscle b -TM
and fibroblast TM-1. The latter is also expressed in smooth
muscle where it corresponds to smooth muscle b -TM.
Skeletal muscle b -TM contains exons 7 and 10, whereas
exons 6 and 11 are used in fibroblasts and smooth muscle.
In order to study the properties of the alternatively spliced
proteins, recombinant TMs derived from bacterial and
insect cell expression systems were produced, including the
normal b gene products, fibroblast TM-1 and b skeletal
muscle TM, two carboxy-terminal chimeric TMs, TM-6/10
and TM-7/11, as well as a carboxyl-truncated version of
each, TM-6Cla and TM-7Cla. The purified TM isoforms
were used in actin filament association studies. The
apparent TM association constants (Ka) were taken as the
free concentration at half saturation and were found to be
6 m M for b Sk TM, 8.5 for TM-6/10, 25 m M for TM-1, and
30 m M for TM-7/11 at an F-actin concentration of 42 m M.
For the truncated TMs, the values determined were higher
still but the binding was not carried out to full saturation.
Isoforms were also produced using the baculovirus-insect
cell system which produces proteins with an acetylated
amino terminus as is normally found in vivo. This modifi-
cation significantly enhanced the F-actin association of
TM-1 but not the b skeletal TM or the other isoforms.
Fibroblast TM-2 or TM-3, both products of the a gene,
enhanced the affinity of TM-1 for F-actin, demonstrating
different isoforms can act cooperatively on binding to actin.
This effect was not detected with the other expressed b gene
products. The presence of 83 kDa nonmuscle caldesmon
was found to enhance the binding of TM-1 for F-actin. This
effect was dependent on the presence of both exons 6 and
11, as caldesmon had little effect on the other b gene
products. Collectively these results demonstrate TMs differ
in their affinity for F-actin, which can be altered by other
TMs or actin-binding proteins. The b tropomyosin
isoforms were fluorescently-tagged and microinjected into
cultured cells to study their in vivo localization where it was
found that each of the full-length TMs bound to microfila-
ments but, at the light microscopy level, the isoforms were
not differentially localized in these fibroblasts.
Key words: b tropomyosin gene, F-actin, caldesmon, alternative
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SUMMARYINTRODUCTION
Most microfilaments have tropomyosin (TM) bound along
their length, in the long pitch grooves on either side of the 2-
start actin filament helix. The assembly and disassembly of
microfilaments is a dynamic process repeated many times in a
locomoting fibroblast. In addition, once every cell cycle, the
complete actin network must be disassembled in readiness for
mitosis, and later reassembled. How the association of TMs
with actin is regulated is unknown. In the rat, there are known
to be sixteen TM proteins expressed from four genes through
the use of different promoters and alternative RNA processing.
In skeletal muscle, the tropomyosin exists as a heterodimer
consisting of one polypeptide from the a gene (a skeletal
muscle TM, 284 amino acids) and one polypeptide from the b
gene (b skeletal muscle TM (b Sk TM), 284 amino acids). In
smooth muscle, the heterodimer is also formed from onepolypeptide from the a gene and one polypeptide from the b
gene, but each is an alternatively spliced product and differs in
two exons from the skeletal muscle counterparts. In cardiac
tissue, the TM dimer is composed only of a gene product, two
chains of the a skeletal TM. There is a wider variety of
tropomyosin isoforms in nonmuscle tissues owing to the
expression of the four genes, three of which are alternatively
spliced. This can result in the expression of as many as eight
TM isoforms in a given cell. The cloning of the cDNAs for
TMs has led to a better appreciation of the complexity of
tropomyosin expression in vertebrates. For example, in rat
fibroblasts, the a gene produces TM-2, TM-3, TM-5a and TM-
5b through the use of two promoters and alternative mRNA
processing (Goodwin et al., 1991). These differ in their affinity
towards F-actin in the order 5b>2=3>5a, with the 248 amino
acid TM-5b capable of displacing the 284 amino acid TM-2
(Pittenger and Helfman, 1992). In this study the F-actin asso-
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was not cooperativity between isoforms, with each appearing
to compete for F-actin binding sites. The a gene can also
produce three brain specific isoforms (Lees-Miller et al., 1990)
which are differentially expressed in neuronal cells during
development (Stamm et al., 1993) or induced during neurite
out growth in PC12 cells (Weinberger et al., 1993). In most
smooth muscle and nonmuscle tissues, the b gene expresses
only one isoform, TM-1. This TM differs from the b gene
product found in skeletal muscle (b Sk TM) by the inclusion
of an alternative internal exon (exon 6 in place of exon 7) and
an alternative carboxy-terminal exon (exon 11 in place of exon
10, see Fig. 1) (Helfman et al., 1986; Yamawaki-Kataoka and
Helfman, 1985). The functional differences between these
isoforms are unknown. 
While our knowledge of the TM gene family has progressed
rapidly in recent years (see Lees-Miller and Helfman, 1991 for
review), there is not as yet a clear understanding of the function
and regulated expression of nonmuscle TM proteins. The com-
plexity of TM isoform expression is probably not due to func-
tional redundancy, as this complexity has been largely main-
tained through evolution suggesting important functions that
have been conserved through selective pressures. What roles
the different isoforms of TM fulfill in evolutionarily diverse
organisms is unclear. TM’s function in striated muscle con-
traction has been well studied and tropomyosin facilitates the
calcium-sensitive contraction of muscle fibers either by a steric
blocking mechanism (Ebashi et al., 1969) or through allosteric
interactions (Greene and Eisenberg, 1980). In smooth muscle,
our understanding is less complete, but the phosphorylation of
associated proteins, notably caldesmon and the myosin light
chains, is involved in regulating actin and myosin association
(Marston and Smith, 1985). A greater challenge still is to
unravel the roles nonmuscle TMs play in different tissue types,
given the variety of dynamic actin based structures present in
cells. What properties the alternatively spliced exons confer on
the TM isoforms is beginning to be elucidated (reviewed by
Pittenger et al., 1994) but in order to better understand the char-
acteristics of individual TMs, purified isoforms are necessary.
The purification of nonmuscle TM isoforms from endogenous
sources has proven difficult owing to their very similar
physical and chemical properties. However, several investiga-
tors have taken advantage of the availability of cDNA clones
for TMs and bacterial expression systems to generate quanti-
ties of individual isoforms for biochemical (Bartegi et al.,
1990; Cho et al., 1990; Montiero et al., 1994; Novy et al.,
1993a,b; Pittenger and Helfman, 1992; Urbancikova and
Hitchcock-DeGregori, 1994; this paper) and cellular studies
(Pittenger and Helfman, 1992; Prasad et al., 1993; this paper).
The results have shown that many of the TM isoforms
produced in bacteria can readily bind to F-actin in vitro (Cho
et al., 1990; Heald and Hitchcock-DeGregori, 1988; Novy et
al., 1993a,b; Pittenger and Helfman, 1992) but that certain TMs
require an intact amino terminus or some form of amino
terminal extension (Cho et al., 1990; Heald and Hitchcock-
DeGregori, 1988; Montiero et al., 1994; Urbancikova and
Hitchcock-DeGregori, 1994). When the isoforms that readily
bind to actin filaments in vitro were introduced into cultured
cells by microinjection, all were able to compete with the
endogenous isoforms and incorporate into the microfilaments
and in all cases, appeared to have no detrimental effects oncells (Pittenger and Helfman, 1992; Ranucci et al., 1993; this
paper). As yet, the isoforms that have been introduced into
cells have not shown differential localization as has been
reported using an isoform-specific antibody (Lin et al., 1988).
In this paper, we report the characterization of recombinant
TMs derived from the b gene using bacterial and insect cell
expression systems. F-actin association of TM-1 (which
contains the alternatively utilized exons 6 and 11) is shown to
be affected by the presence of an acetylated amino terminus,
the presence of TM-2, or the 83 kDa nonmuscle caldesmon.
The b Sk TM (which contains the exons 7 and 10 in place of
exons 6 and 11, respectively) showed little such effects. For
those isoforms which bound well to actin in vitro, microfila-
ment staining was easily visualized. However, no preferential
localization to particular regions of the cell was seen with the
labeled proteins. Our previous results also showed that the a
gene products TM-2, TM-3, TM-5a and TM-5b showed indis-
tinguishable microfilament staining when fluorescently labeled
isoforms were introduced into fibroblasts by microinjection
(Pittenger and Helfman, 1992). Taken together, the results
suggest that most TMs do not achieve their function through
differential localization within the cell. However, the organiz-
ation of particular TM isoforms along actin filaments is
probably not random and may be modified by the presence of
other TMs or other actin binding proteins. A discussion of the




The cDNA clones for rat fibroblast TM-1 and b Sk TM have been
described (Helfman et al., 1986; Yamawaki-Kataoka and Helfman,
1985). Molecular biology techniques were carried out as described
(Sambrook et al., 1989). The bacterial expression plasmid pET8C
(Studier et al., 1990) DNA was digested with NcoI and BamHI and
the larger vector fragment gel purified. The TM-1 coding sequence
was removed from SP64 vector by complete digestion with BamHI
and partial digestion with NcoI and the correct fragment isolated by
gel purification. The b Sk TM coding sequences present in clone
SK22 (Helfman et al., 1986) were removed from pUC9 vector
sequences by NcoI (single site) and BamHI digestion followed by gel
purification. These TM coding sequences were then ligated into the
NcoI/BamHI cleaved pET8C. Bacterial expression vectors to produce
chimeric protein hybrids TM-7/11 and TM-6/10 were constructed by
swapping the sequences 3¢ of the ClaI site to the SalI site between
plasmids SP65 TM-1 and SP65 b Sk TM (this was done by Dr Susan
Erster, for other purposes in this laboratory). Subsequently, the 3¢ SalI
site was converted to a BamHI site by digestion with SalI followed
by nucleotide fill-in with the large fragment of Escherichia coli DNA
polymerase I (Klenow fragment) and addition of BamHI linkers. The
plasmids were then exhaustively digested with BamHI. The TM-7/11
construct was cut with NcoI and the proper fragment isolated. The
TM-6/10 construct contained two NcoI sites so a partial digest was
performed and the correct fragment isolated. These fragments were
ligated overnight to the NcoI/BamHI digested pET8C. Competent 
E. coli was transformed with a portion of the ligation reaction, grown
overnight, and colonies checked for appropriate inserts and then
selected clones sequenced by the dideoxy-chain termination method
(Sanger et al., 1977). Correct DNA constructs were tested for the 
production of TM proteins upon transformation of BL 21 (DE3)
bacteria as described (Pittenger and Helfman, 1992). To produce
truncated versions of TM-1 and b Sk TM lacking the alternative
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construct was digested with ClaI, which cleaves in the conserved exon
9 at codon 254, and BamHI. The large fragment was isolated after gel
electrophoresis, the ends filled by use of Klenow fragment, and the
plasmid religated. This results in a vector that produces a truncated
tropomyosin of 257 amino acids with the last four amino acids being
coded by vector sequences before a termination codon is encountered. 
For the production of acetylated TMs from SF9 cells, the TM
inserts were removed from the pET8C vectors as XbaI (upstream of
the NcoI site and downstream of the bacteriophage f 10 promoter) to
BamHI fragments and inserted at the XbaI/BamHI position down-
stream of the polyhedrin promoter of the baculovirus vector pVL-
1392 (PharMingen, San Diego, CA). The linearized virus DNA con-
taining a lethal deletion (BaculoGold, from PharMingen) was
cotransfected with the pVL 1392-TM constructs into SF9 cells
(American Type Culture Collection, Bethesda, MD). Recombinant
viable virus particles in the cell media were passed to new cultures
every fourth day and after three rounds of infection the cells were
tested for production of TM proteins by polyacrylamide gel elec-
trophoresis.
The rat 83 kDa nonmuscle caldesmon was expressed in host
bacteria BL21 (DE3) pLys-S using a full length cDNA clone in pET-
11d vector (Novagen, Madison, WI) and purified as described
(Yamashiro-Matsumura et al., 1988). This particular construct
contained a myc epitope tag (EQKLISEEDL) at the amino terminus,
away from the actin- and tropomyosin-binding regions of the C
terminus that was useful to follow the purification of the protein.
Purification of expressed proteins from baculovirus and
bacteria
The TMs expressed in bacteria were purified as previously described
(Pittenger and Helfman, 1992). The TMs from the baculovirus
expression system were purified by similar methods. Briefly, ten 150
cm plates of SF9 cells (70% confluent) were infected with 4 ml each
of virus stock (approximately 105 pfu/ml) for 4 hours and 15 ml of
additional medium was then added. After three days, the cells were
harvested by gentle scraping and the cells pelleted at 100 g for 15
minutes at 4°C. The cell pellet was saved and resuspended in 4
volumes of hypotonic buffer (30 mM KCl, 10 mM Hepes, pH 6.8, 1
mM EDTA, 1 mM DTT, 1 mM Pefabloc (Boerhinger-Mannheim) and
transfered to a Dounce homogenizer. Triton X-100 was added to the
homogenizer to a final concentration of 0.5%. After 10 strokes, 2 M
KCl was added to bring the concentration to 200 mM. The
homogenate was spun at 100,000 g for 1 hour and the supernatant
saved. The supernatant was brought to 600 mM KCl and the solution
heated to 70°C for 15 minutes and denatured proteins were pelleted
at 30,000 g for 15 minutes at 4°C. The TM remaining in the super-
natant was precipitated by the addition of potassium acetate (pH 4.5)
to a final concentration of 30 mM. After 20 minutes on ice, the pre-
cipitate was pelleted at 3,000 g, and the pellet was resuspended in one
original volume of buffer (100 mM KCl, 20 mM sodium phosphate,
pH 7.0, 1 mM DTT) and the pH adjusted to pH 7 by dropwise addition
of 2 N sodium hydroxide. Any material not in solution was pelleted
by centrifugation and discarded. The pH precipitation step was
repeated twice more and the final pH 4.5 pellet was resuspended in
30 mM KCl, 20 mM sodium phosphate, pH 7, 1 mM DTT and this
was loaded onto a 5 ml anion exchange column (Mono Q resin,
Pharmacia). The column was washed with three column volumes and
the TMs were then eluted with a gradient of 30-600 mM KCl (also
containing 20 mM sodium phosphate, pH 7.0, and 1 mM DTT) in 30
column volumes. Fractions were analysed by SDS-PAGE and appro-
priate fractions pooled and stored on ice or at minus 70°C for long
term storage. The yield of expressed protein from insect cells varied
from 4-15 mg depending on the TM isoform.
The full length nonmuscle caldesmon cDNA from rat was
expressed in bacteria using the pET vector. This construct contained
the myc epitope at the amino terminus, away from the putative actinand tropomyosin binding regions. Caldesmon expression was induced
with 0.4 mM IPTG and cells harvested 2 hours later. Purification was
accomplished as described (Yamashiro-Matsumura et al., 1988)
following the initial lysis and centrifugation (Pittenger and Helfman,
1992). Myc epitope antibodies (Oncogene Science, Uniondale, NY)
were used to follow purification by western blotting procedures as
well as Coomassie Blue staining of SDS-PAGE gels. The yield of
caldesmon was much less than for tropomyosin, approximately 1 mg
per liter of culture. For the experiments described here, the final purifi-
cation step involved F-actin binding and repurification as described
(Pittenger and Helfman, 1992). 
Protein sequencing
NH2-terminal sequencing was carried out at the Protein Core Facility
at Cold Spring Harbor Laboratory essentially as described (Matsu-
daira, 1987). Results for the first eight cycles are shown in Table 1,
with the yield in pmol for each cycle. For the bacterially expressed
proteins, the amino acid sequences determined were the correct amino
and carboxy termini predicted from the known cDNA codons. The
same coding sequences were used for expression in SF9 cells. The
TMs produced in SF9 cells could not be sequenced from the N
terminus and proved to have blocked amino termini, presumably due
to acetylation, which is known to occur in this expression system. The
proteins were of the correct size and on 2-D gels, migrated virtually
identically to the bacterially produced full length proteins or TMs
partially purified from cultured cells (data not shown). The carboxy
terminus of the TMs in bacterial expression plasmids were sequenced
using an oligo complementary to internal sequences and reading 5¢ to
the plasmid squences. For several of the proteins, carboxy-terminal
sequencing was carried out using the amino acid analysis of those
residues released by carboxypeptidase Y digestion over time
(Pittenger and Helfman, 1992) and provided evidence of correct full
length TM proteins (data not shown). The recombinant proteins
truncated at the ClaI site were not subjected to protein sequencing but
the expression plasmid for TM-7Cla was sequenced and the expressed
proteins were of the expected molecular mass on SDS-PAGE gels.
F-actin binding assay
F-actin binding assays were performed as described (Matsumura and
Yamashiro-Matsumura, 1985; Novy et al., 1993a; Pittenger and
Helfman, 1992) or in a buffer containing 100 mM KCl, 30 mM NaCl,
20 mM sodium phosphate, pH 7.0, 0.5 mM EGTA and 1 mM DTT.
The results in the two buffers were comparable. Routinely, incuba-
tions were for one hour at room temperature in a 70 m l volume,
followed by sedimentation in an Airfuge (Beckman Instruments, Palo
Alto, CA) at 28 psi for 30 minutes or a TLA-100 rotor at 65,000 rpm
in the tabletop ultracentrifuge (Beckman Instruments). After cen-
trifugation, the supernatant was removed and mixed with an equal
volume of 2· SDS gel sample buffer. The pellet was carefully resus-
pended in 140 m l of 2 · SDS gel sample buffer. Samples (10 m l) of
supernatants and pellets were loaded on 12% polyacrylamide gels
using the discontinuous buffer system (Laemmli, 1970). Binding
assays were quantified using scanning densitometry as previously
reported (Matsumura and Yamashiro-Matsumura, 1985; Novy et al.,
1993a; Pittenger and Helfman, 1992) using as standards TMs whose
concentration were determined by amino acid analysis in the Protein
Core Facility at Cold Spring Harbor Laboratory. All binding studies
were performed using 42 m M actin. 
Fluorescent labeling of proteins and microinjection
Fluorescent labeling of TMs produced in bacteria or SF9 cells was
carried out as previously described (Pittenger and Helfman, 1992).
Microinjection of cultured cells was performed by published proce-
dures (Diacumakos, 1973; Graessmann et al., 1979) as detailed pre-
viously (Pittenger and Helfman, 1992).
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Fig. 1. Diagram of the rat b tropomyosin gene products and the
expression vectors used in this study. (A) Shown is the exon
organization of the b gene (using the numbering of exons according
to Helfman et al., 1986) and the two alternatively spliced products,
skeletal muscle b TM and fibroblast TM-1 (identical to smooth
muscle b TM). The two chimeric proteins TM-7/11 and TM-6/10
were created by exchanging the sequences downstream of the ClaI
site, the numbering representing the exons used in each isoform.Cell culture methods
Cultured rat embryo fibroblasts (REF 52) were grown in DME
medium (Gibco BRL, Grand Island, NY) containing 10% rhehatuin
fetal calf serum (Intergen, Purchase, NY), 4,500 mg/l glucose, 50 mg/l
streptomycin, 50 U/ml penicillin G. Cells were grown in a 5% CO2
atmosphere at 37°C. SF9 cells were obtained from PharMingen or the
American Type Culture Collection (Rockville, MD) and were grown
in TMN-FH media (Sigma Chemical Co., St Louis) supplemented
with 10% fetal calf serum and 1 U/ml gentamycin, at 27°C without
CO2.
RESULTS
Production of tropomyosins in bacteria and insect
cells
The bacterially produced TMs included fibroblast TM-1 and b
Sk TM, as well as two chimeric TMs, in which the C-terminal
domain of each isoform was exchanged. The resulting chimeric
isoforms are herein referred to as TM-6/10 and TM-7/11 (Fig.
1). It is worth noting that these two chimeric TMs have been
found to be expressed at low levels from the mouse b -TM gene
(Wang and Rubenstein, 1992). In addition to the full-length
TMs, two C-terminal truncated proteins were produced and are
referred to as TM-6Cla and TM-7Cla (Fig. 1). The recombi-
nant TMs were expressed constitutively in bacteria as soluble
proteins but production levels could be increased approxi-
mately two-fold by the addition of IPTG (0.4 mM final con-
centration) to early log phase cultures. Bacteria were harvested
by centrifugation and lysed by a combination of enzymatic
digestion and detergent solubilization. The proteins were
purified as described previously (Pittenger and Helfman, 1992)
by modification of published procedures used to purify TM
from tissue sources including ammonium sulfate precipitation,
pH precipitation of TMs, heat denaturation of contaminating
proteins, and ion exchange chromatography. Purification was
assessed by SDS-PAGE (see Fig. 2) and also by western
blotting, where appropriate. The yield of purified TMs
expressed in bacteria varied depending on the isoform but
ranged from 10 to 40 mg per liter of bacterial culture. The full-
length final products used in subsequent experiments were
greater than 95% pure, the contaminants being mostly
premature termination products or minor degradation products.
Several of the TMs were subjected to N-terminal and C-
terminal sequencing to ensure that they were full length and
retained the N-terminal methionine. The bacterially produced
TMs, TM-1 and b Sk TM, as well as the chimeras TM-6/10
and TM-7/11 were found to have the correct N-terminal
sequence (see Table 1). The carboxy termini of TM-1 andTable 1. Amino-terminal sequence analysis of
recombinant proteins
Cycle TM-1 b Sk TM-7/11 TM-6/10 TM-6Cla TM-7Cla
1 M 28 M 16 M 10 M 6 M 110 M 79
2 D 10 D 9 D 12 D 6 D 85 D 47
3 A 23 A 16 A 12 A 5 A 89 A 62
4 I 12 I 8 I6 I 4 I 59 I 37
5 K 8 K 5 K 10 K 7 K 115 K 68
6 K 12 K 5 K 14 K 8 K 141 K 79
7 K 12 K 5 K 12 K 7 K 130 K 78
8 M 13 M 9 M 9 M 4 M nd M 53TM7/11 were analysed by the release of amino acids over time
with digestion by carboxypeptidase Y which gave evidence of
being full length (data not shown, the amino acid sequence is
278-LLELNNL-284 and therefore somewhat redundant).
TMs were produced in SF9 cells both as suspension cultures
and attached to tissue culture plates. The tropomyosins
produced using the baculovirus expression system were found
to have a blocked amino-terminus as expected, presumably due
to acetylation which is known to occur in this expression
system. The purified proteins were greater than 95% pure (seeTwo truncated versions were also made by cleavage at the ClaI site
(interrupting codon 251), followed by filling the site by use of DNA
polymerase (Klenow fragment) and religation. A missense
termination signal arises from the vector sequences. (B) The
bacterial expression plasmid pET-8c allows the expression of non-
fusion proteins when coding sequences are inserted. The TM
sequences were subcloned as NcoI-BamHI fragments, containing the
initiating methionine as part of the NcoI site, and termination signals
occurring just downstream of the coding sequences, prior to the
BamHI site. (C) For expression in insect cells, the coding sequences
were removed from the pET vector as XbaI to BamHI fragments and
inserted into the vector pVL1392 (Pharmingen Inc.) downstream of
the polyhedrin promoter.
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Fig. 2. Purified b tropomyosins following expression in bacteria. The
tropomyosins were expressed in the bacterial host BL21 containing a
DE 3 lysogen with the IPTG inducible T7 polymerase gene and
purified as described previously (Pittenger and Helfman, 1992); 3 m g
of each TM isoform was resolved on a 12% polyacrylamide gel
containing SDS. Lane 1, TM-7/11; lane 2, TM-1; lane 3, b Sk TM;
lane 4, TM-6/10; lane 5, TM-7Cla; lane 6, TM-6Cla. To the right are
shown the positions of molecular mass markers (· 10- 3). Arrows
mark the top and bottom of the gel.Fig. 4A,B) with minor contaminants being premature termina-
tion products or minor degradation products, as they would
react with tropomyosin antibodies on blots. Based on the initial
wet weight of packed cells, the final yield of purified TMs from
the insect cell expression was approximately one third to one
tenth of the yield from bacteria, depending on the isoform.
F-actin binding assay with purified tropomyosins
In order to assess the actin binding affinity of the TM isoforms,
F-actin binding assays were performed. Increasing amounts of
purified isoforms were incubated with a fixed amount of fila-
mentous rabbit skeletal muscle actin and the F-actin:TM
complex was pelleted by centrifugation. The supernatants were
removed and the pellets resuspended in an equal volume and
aliquots of each were subjected to SDS-PAGE. The resolved
proteins were visualized with Coomassie Brilliant Blue dye.
The amount of TM bound was quantified by gel scanning and
comparison to TM standards whose concentration was previ-
ously determined by amino acid analysis. In these experiments,
the amount of F-actin pelleted was not affected by the bound
TM. Therefore, the individual lanes could be normalized by
comparing the actin amounts present. The results show that
each of the isoforms binds in a saturable manner (Fig. 3). The
association curves are characteristic for each of the isoforms
and were performed several times. The apparent TM associa-
tion constants (Ka) were taken as the free concentration at half
saturation and were found to be 6 m M for b Sk TM, 8.5 for
TM-6/10, 25 m M for TM-1, and 30 m M for TM-7/11, at an
actin concentration of 42 m M. For the truncated TMs, the
values determined were higher still but the binding was not
carried out to full saturation. Bacterially expressed TM-1
bound rather weakly relative to the b Sk TM and the chimeric
TM-6/10. TM-7/11 was also found to bind with a low affinity,
similar to TM-1. It was noted that proteins whose C terminuswas encoded by exon 10 bound actin with much greater affinity
than those containing exon 11. Whether this was an intrinsic
property of the terminal exon or due to improper folding, etc.
is not completely clear. However, eliminating the last exons by
expressing the truncated TMs resulted in similarly weak
binding for each of the truncated forms (see Fig. 3E and F).
Several binding assays were also performed in buffers of
varying ionic strength (30 to 120 mM KCl) with similar results
and no change in the relative affinity of the TMs for F-actin
(data not shown).
Acetylation of the amino terminus enhances TM-1
binding to filaments
When tropomyosins isolated from endogenous tissue sources
have been sequenced, they have proven to have an acetylated
amino terminus as is found for many proteins. Due to the head-
to-tail overlap which is known to occur for certain TMs bound
along the actin filament, this acetylation may be important for
proper alignment and cooperative binding. In order to directly
ask whether the acetylation of the amino terminus affects the
actin affinity of TM-1, we expressed this isoform in an insect
cell expression system. The SF9 insect cells are known to carry
out protein modifications such as acetylation and limited gly-
cosylation. When expressed in SF9 cells, TM-1 and other
isoforms were unable to be sequenced from the amino
terminus, presumably due to acetylation. Using this TM-1 in
the F-actin binding (Fig. 5a,b) assay, a distinct increase in the
binding was evident, with a decrease in the apparent associa-
tion constant from 25 m M to 10 m M. When the TM a gene
product TM-2 was produced in the bacterial and insect cell
system and the products tested for their ability to bind F-actin,
only a slight increase in association was found (Fig. 5c,d).
Similarly, for the b Sk TM expressed in SF9 cells, no increase
in binding was evident when compared to the bacterially
expressed Sk TM. This suggests that for those TMs that readily
bind F-actin, this amino terminal acetylation has limited or no
effect, but that for certain isoforms it may be critical. 
Presence of other tropomyosins can promote TM-1
association with actin filaments
Tropomyosin binding to F-actin has been shown to involve
cooperative interactions, due in part to head-to-tail overlap of
coiled coil dimers. In addition we have demonsrated previously
using a TM isoforms expressed in bacteria, that the nonmuscle
isoform TM-5b could compete and displace the TMs 2, 3 or
5a from F-actin (Pittenger and Helfman, 1992). In order to test
whether the presence of other TMs would affect the binding of
TM-1, mixtures of expressed isoforms were incubated with F-
actin. As expected, TM-5b (expressed in bacteria) could
displace TM-1 (data not shown). Surprisingly, we found that
when increasing amounts of TM-1 (expressed in bacteria or
insect cells) were incubated with F-actin for one hour and then
equimolar amounts of TM-2 were added for an additional hour,
TM-1 binding was increased at low concentrations and
inhibited at higher concentrations (see Fig. 6). When TM-2 was
present, TM-1 binding appeared to saturate at 15 m M (0.5
mg/ml), lower than the 45 m M (1.5 mg/ml) concentration
necessary in the absence of TM-2. However, the amount of
TM-1 bound at saturation was lower than in the absence of
TM-2. This inhibition never precluded TM-1 binding, but
amounts of TM-2 which saturate the actin filaments failed to
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b
Fig. 4. (A) The purification of TMs expressed in insect cells. TM
isoforms were purified following procedures similar to those used to
prepare TMs expressed in bacteria. Lane 1, detergent lysed SF9 cells
expressing TM-1. Lane 2, S100 supernatant fraction. Lane 3, S100
pellet. Lane 4, first pH precipitation pellet from S100 supernatant.
Lane 5, supernatant from 4. Lane 6, pellet from second pH
precipitation. Lane 7, supernatant from 6. Lane 8, resuspended TM at
pH 7.5 from third pH precipitation pellet prior to loading onto Mono
Q column. Lane 9, pellet from centrifugation prior to loading Mono
Q column (pH 7.5). Lane 10, flow-through from Mono Q column.
Lane 11, 10 m g of TM-1 from pooled peak of protein from Mono Q
column. (B) Purified bacterially expressed 83 kDa caldesmon (lane
1) and purified TM-2 expressed in insect cells. Each isoform was
purified as described and 3 m g of each protein was electrophoresed
through a 12% SDS-polyacrylamide gel. Minor bands in the
caldesmon preparation are breakdown products. Arrows identify the
positions of full length proteins.
Fig. 3. Binding of the recombinant tropomyosins to filamentous
actin. (a) The ability of the different tropomyosins to associate with
F-actin was tested by a sedimentation assay. F-actin at a
concentration of 1 mg/ml in a buffer of 100 mM KCl, 1 mM DTT,
20 mM sodium phosphate, pH 7.0, was incubated with decreasing
amounts of each purified tropomyosin isoform produced in bacteria.
The associated TM was then pelleted with the filamentous actin in an
airfuge or tabletop ultracentrifuge. The supernatants and pellets were
brought to the same final volume with SDS gel sample buffer and
equal aliquots were resolved on a 12% SDS-polyacrylamide gel and
visualized by Coomassie Brilliant Blue R. Tropomyosin
concentrations are: lane 1, 1 mg/ml TM; lane 2, 0.75 mg/ml; lane 3,
0.5 mg/ml; lane 4, 0.25 mg/ml; lane 5, 0.125 mg/ml; lane 6, 0.06 mg
ml. (b) The data from (a) was quantified by densitometry and plotted
as described in Results.
adisplace the bound TM-1. And the presence of TM-1 did not
alter the extent of TM-2 binding. This was also true when
samples were incubated for longer periods (up to 4 hours) and
the result does not appear to be kinetically limited. Thus it
appears that TM-1 in the presence of TM-2 binds to a limited
number of sites on actin filaments and that TM-2 facilitates
such TM-1 binding in a cooperative manner. From quantify-
ing the Coomassie Blue stained gels, the molar amounts of TM
bound when each TM was at saturation appeared to be 1:6,
TM-1 to TM-2. TM-1 binding was similarly increased when
TM-3, another 284 amino acid a gene product, was present
(data not shown). It should be noted that the amount of TM-2
bound appeared to be the same in the presence or absence of
TM-1, but small changes of 5-10% would be within experi-
mental error and difficult to quantitate. However, this did not
appear to be the case. Preliminary experiments involving more
than two isoforms of TM became difficult to interpret without
careful quantitation and are beyond the scope of the current
work.
Caldesmon enhances TM-1 binding to actin
filaments
Caldesmon is known to bind both actin and tropomyosin
through residues in the carboxy third of the elongated molecule
(Watson et al., 1990) although the exact binding sites and
overlaps are not completely known. We tested whether 83 kDa
3259Alternatively spliced exons of the b tropomyosin genenonmuscle caldesmon would affect the F-actin binding of the
different expressed TMs. The caldesmon was expressed in
bacteria which produces an unphosphorylated CaD, the form
that readily binds F-actin (Yamashiro et al., 1990). TM-1
exhibited greatly enhanced binding even at subsaturating
amounts of caldesmon (Fig. 7). By contrast the binding of the
other TM isoforms was not dramatically affected by caldesmon
(Fig. 7). The increase in binding of TM-1 lowered the half-sat-
urating amount of TM-1 from 0.75 mg/ml to approximately 0.4
mg/ml with an estimated decrease in Ka from 25 m M to about
8-10 m M. When caldesmon was first allowed to incubate with
F-actin for one hour and TM-1 was subsequently added for an
additional hour, the results were identical, suggesting that a
TM-1:caldesmon complex is not first required for binding.
When TM-1 and caldesmon were incubated in the absence of
F-actin and subjected to centrifugation, no pellet was formed
(data not shown). Acetylated TM-1 produced in the insect cell
expression system also showed a large increase in binding in
the presence of nonmuscle caldesmon (Fig. 7d), suggesting that
the enhancement in binding is more than simply an alteration
in the TM-1 amino terminus (see Discussion). The amount of
pelleted F-actin did not change, nor did the extent of caldesmon
binding when TM-1 was present. As shown in Fig. 8a, theFig. 5. Acetylated TM-1 produced in insect cells shows enhanced F-
actin association compared to unacetylated bacterially expressed
TM-1. (A and B) Binding of bacterially expressed TM-1 is shown in
A and the binding of the acetylated form expressed in baculovirus is
shown in B. Solid arrow indicates the position of the Tm isoform on
the gel, while the open arrow indicates the position of actin. F-actin
at 1 mg/ml was incubated with decreasing amounts of TM (1.0, 0.75,
0.5, 0.25, 0.125, 0.06 mg/ml for lanes 1-6, respectively) and the actin
pelleted by centrifugation. There was enhanced binding of the
acetylated form of TM-1 produced in insect cells relative to that
expressed in bacteria. (C and D) Only a slight change in the affinity
of TM-2 for actin was found when it was expressed in insect cells
(D) as compared to that expressed in bacteria (C).chimeric TM-6/10 also showed an enhancement in binding in
the presence of nonmuscle caldesmon, but not as dramatic as
the TM-1. The expressed TM-7/11, TM-6Cla and TM-7Cla
showed only a slight, if any enhancement in binding when
caldesmon was present. Clearly the greatest enhancement of
TM binding was seen with TM-1 which utilizes exons 6 and
11.
Microinjection of fluorescently tagged TMs
In order to try to identify any differences in the subcellular
localization of the isoforms each of the bacterially produced b
TM isoforms was fluorescently labeled by reaction with
lissamine rhodamine B sulfonyl chloride and the labeled TMs
used in microinjection experiments. The proteins were
microinjected into REF52 cells, a rat embryo fibroblast cell
line with a well-spread morphology. These cells have been
used previously for the microinjection of a -TM isoforms
(Pittenger and Helfman, 1992) and the expression of TMs in
these cells has been well studied (Matsumura and Yamashiro-
Matsumura, 1985; Matsumura et al., 1983).
The microinjection of b Sk TM and TM-6/10, isoforms
which utilize exon 10, resulted in rapid and extensive incor-
poration into the microfilament system. As shown in Fig. 9,
within 30 minutes after injection, labeling was seen through-
out the cell, but was most intense near the site of injection.
Labeling was also present at the cell periphery, where active
reorganization of microfilaments is known to occur (Theriot
and Mitchison, 1992). By 2 hours, the labeling was virtually
uniform within the cell and characteristic tropomyosin stri-Fig. 6. F-actin binding assay reveals TM-2 enhances the binding of
TM-1 to F-actin. The binding of TM-1 to F-actin was found to be
enhanced when TM-2 was present. At low concentrations of TM-1,
there was enhanced binding to F-actin when equimolar levels of TM-
2 were present. At saturating levels of TM-2, TM-1 could still bind
to actin filaments, but to a lower saturating level than when TM-2 is
absent. The presence of TM-1 did not appear to effect TM-2:actin
association. (A) Bacterial TM-1 alone binding to F-actin. 
(B) Bacterial TM-2 alone binding to F-actin. (C) Equal amounts of
bacterially expressed TM-1 and TM-2 binding to F-actin. Lanes 1 to
5, 1 mg/ml actin. Lane 1, 1 mg/ml TM. Lane 2, 0.5 mg/ml of each
TM. Lane 3, 0.25 mg/ml of each TM. Lane 4, 0.125 mg/ml of each
TM. Lane 5, 0.06 mg/ml of each TM. Lane 6, 1 mg/ml of each TM
but no actin present.
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Fig. 7. Caldesmon (83 kDa) enhances the TM-1 association to F-
actin. Assays were performed to analyse the effect of nonmuscle
caldesmon on the binding of TM isoforms to actin filaments. For
this, the TM concentration of each isoform was that at the midpoint
of the binding curve which would show the greatest change, when
caldesmon has an effect. Decreasing amounts of the bacterially
expressed nonmuscle caldesmon were added to the constant amount
of TM isoform and 1 mg/ml of F-actin. A large change in the
association of TM-1 with F-actin was noted as caldesmon was added
up to 0.25 mg/ml. (A) Caldesmon alone. Small arrowheads identify a
caldesmon breakdown product that occurs during bacterial
expression. (B) 0.125 mg ml b Sk TM. (C) 0.25 mg/ml TM-1.
Caldesmon concentrations were: lane 1, 1 mg/ml; lane 2, 0.75
mg/ml; lane 3, 0.5 mg/ml; lane 4, 0.25 mg/ml; lane 5, 0.125 mg/ml;
lane 6, 0.06 mg/ml.
Fig. 8. Caldesmon has limited effect on the other b TM isoforms.
The effect of caldesmon on the binding of the chimeric b TMs and
the truncated forms to F-actin was tested. A limited effect was seen
with TM 6/10 (A) but little or no effect was seen with TM-7/11 (B),
TM-6Cla (C) or TM-7Cla (D). Concentration of TM 6/10 was 0.125
mg/ml; TM 7/11 was 0.25 mg/ml; TM-6Cla was 0.25 mg/ml; TM-
7Cla was 0.25 mg/ml. As in Fig. 7, caldesmon concentrations were;
lane 1, 1 mg/ml; lane 2, 0.75 mg/ml; lane 3, 0.5 mg/ml; lane 4, 0.25
mg/ml; lane 5, 0.125 mg/ml; lane 6, 0.06 mg/ml. Small arrowheads
identify a caldesmon breakdown product.ations were visible on stress fibers. Counterstaining actin
filaments with fluorescein phalloidin revealed that at the light
microscope level essentially all actin filaments had incorpo-
rated the microinjected TM. There appeared to be no deleteri-
ous effects on filament stability or cell viability, and labeledfilaments could be found in microinjected cells as late as 48
hours. Therefore, these two isoforms, although not normally
found in these cells could readily compete with endogenous
TMs and incorporate into microfilaments. They did not cause
morphological changes in these well spread cells, nor did there
appear to be any detrimental short term effects on cells.
When bacterially expressed TM-1 and TM-7/11 were
similarly labeled, microinjected and allowed to incorporate,
only the faintest of filament staining was discernable (data not
shown). This weak incorporation appeared to be consistent
with the F-actin binding results and previous microinjection
experiments (Pittenger and Helfman, 1992), suggesting that
preparations of TMs that bound poorly to actin filaments in
vitro were unable to label microfilaments following microin-
3261Alternatively spliced exons of the b tropomyosin genejection. The presence of TM-2 and caldesmon within these
cells apparently failed to enhance binding sufficiently.
However, when TM-1 was produced in insect cells, fluor-
escently labeled and microinjected, extensive incorporation
into microfilaments was seen (Fig. 10a). The labeling was not
as intense as for b Sk TM or TM-6/10 but this may reflect the
limited incorporation of TM-1 in the presence of other
isoforms as seen in the F-actin binding assay (Fig. 6c). 
DISCUSSION
Binding of b TM gene products to F-actin
The seven or eight tropomyosin isoforms found in fibroblasts
are an integral part of the microfilament system and are thought
to play a role in microfilament dynamics (Ishikawa et al.,
1989a,b; Nishida et al., 1985). Tropomyosins are present as
coiled coil dimers, which in fibroblasts have been shown to be
homodimers (Lin et al., 1985; Matsumura and Yamashiro-
Matsumura, 1985; M. Gimona, A. Watakabe and D. M.
Helfman, unpublished) while in smooth and striated muscle,
TMs form heterodimers of one a and one b subunit. The
intrinsic affinity of different TM homodimers towards F-actin
has been shown to be quite different, whether the TMs areFig. 9. Time course of incorporation of fluorescently tagged b Sk TM m
microinjected TM isoforms would incorporate preferentially at particul
TMs were microinjected into cultured rat fibroblasts (REF 52 cells). In 
B and the free dye removed by chromatography. The labeled TM was b
denatured TM. The pelleted TM was then separated from actin (see Ma
times following injection, the coverslips were extracted for exactly 5 m
allow unincorporated TM to diffuse away and the cells were then fixed 
microinjection. (B) Five minutes after microinjection. (C) At 30 minute
indicate the site of injection. The incorporation of TM into microfilame
appeared to occur along filaments. Uniform labeling of all microfilamen
phalloidin labeled filaments (data not shown). prepared from endogenous sources (Broschat and Burgess,
1986; Matsumura and Yamashiro-Matsumura, 1985) or from
a heterologous expression system (Novy et al., 1993a,b;
Pittenger and Helfman, 1992; Prasad et al., 1993). In order to
investigate the association of b tropomyosin gene products
with F-actin and microfilaments, we have expressed the
cDNAs for the different isoforms in bacteria and insect cells
and tested the ability of the purified isoforms to bind to actin
filaments in vitro and microfilaments in vivo. Purified TM-1
expressed from bacteria bound weakly to F-actin, while the
acetylated version of this protein produced by expression in
insect cells was found to bind F-actin much more readily, sug-
gesting a structural requirement that this protein fulfills.
Whether this increased binding results from a better fit to
binding sites on actin or is due to a head to tail interactions of
overlapping adjacent TMs or perhaps another factor remains to
be determined. In addition, the b Sk TM and the chimera TM-
6/10, which both use the same C-terminal exon were found to
have a greater F-actin affinity than TM-1 or the chimera TM-
7/11. Exon 10 appears to provide for enhanced actin binding
ability relative to exon 11. Hence, the ends of the linear b TM
molecules have important structural information for actin 
association. Other investigators working with homodimers of
bacterially expressed a Sk TM have shown that its binding toicroinjected into cultured rat fibroblasts. In order to discern whether
ar regions of the cell or sites on microfilaments, fluorescently labelled
this figure, b Sk TM was fluorescently labeled with lissamine rhodamine
ound to F-actin and subjected to centrifugation to eliminate any
terials and Methods) and used for microinjection. At the appropriate
inutes with 0.2% Triton X-100 in a cytoskeletal stabilizing buffer to
in 4% formaldehyde for 30 minutes. (A) Two minutes after
s after microinjection. (D) At 2 hours after microinjection. Arrows
nts at early time points centered around the site of injection and
ts was found by 2 hours post injection, and coincided with all
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that may be overcome by addition of as little as two amino
acids (Montiero et al., 1994) or as many as eighty amino acids
(Cho et al., 1990) to the amino terminal methionine of Sk a
TM homodimers. It is interesting to note that the b Sk TM does
not seem to require N-terminal acetylation while the a Sk TM
does for the homodimers to have ‘high’ F-actin binding. There
is a high degree of conservation between the amino acid
sequences of these proteins. The first 18 amino acids are
identical between the a and b Sk TMs, there also being 3 con-
servative changes in the first 38 amino acids (see Lees-Miller
and Helfman, 1991). The comparison of exons 2b from the a
and b genes reveals 9 differences in 42 residues, 5 being non-
conservative, usually a charged residue in b Sk TM replacing
a neutral or more hydrophobic residue found in a Sk TM. In
the C-terminal coding exons of the a and b genes there are 5
encoded amino acid differences, most of which are conserva-
tive in nature. It will be of interest to determine if these are
sufficient to explain the differences in F-actin binding between
recombinant a and b skeletal muscle isoforms.
a TM gene products enhance association of TM-1
for F-actin
In skeletal and smooth muscle, the TM exists as a coiled coil
heterodimer of one a and one b TM molecule. While virtually
all cell types do express proteins from several TM genes, in
fibroblasts the seven or eight isoforms of TMs are likely to
function as homodimers (Lin et al., 1985; Matsumura and
Yamashiro-Matsumura, 1985; M. Gimona, A. Watakabe andFig. 10. b gene TM isoforms show the same localization following micr
lissamine rhodamine B and purified as described in Fig. 9. (A) Acetylate
(C) b Sk TM produced in bacteria. (D) Rabbit skeletal muscle TM, a mi
complete in 2 hours (see Fig. 9) for 6/10ch, b Sk TM or TM from rabbit
images for TM-1 were obtained 12-18 hours after microinjection. Hence
produced in bacteria as well as the two truncated isoforms TM-6Cla and
to levels which allowed visualization. D. M. Helfman, unpublished). These TM homodimers could
bind to actin filaments and function cooperatively or competi-
tively. For example, we have previously shown that, among the
a gene products, 248 amino acid TM-5b could competitively
displace the 284 amino acid TM-2 or TM-3 from actin
filaments in vitro (Pittenger and Helfman, 1992). As shown in
Fig. 6, the presence of TM-2 enhanced the affinity of TM-1 for
F-actin but limited the extent of binding. In another series of
experiments (data not shown) TM-3 had the same effect on the
association of TM-1 for F-actin as TM-2 but TM-5b appeared
only to compete with TM-1. When TM-1 and TM-2 were both
present, TM-5b continued to compete them both, about
equally, from F-actin (data not shown).
If TMs stabilize microfilaments in vivo (Ishikawa et al.,
1989a; Nishida et al., 1985), cells failing to express a full com-
plement of TM isoforms may exhibit greater microfilament
instability and may never establish stable actin networks or
stress fibers. This seems to be the case for many transformed
cells and suppression of the synthesis of certain TM isoforms
is common following oncogenic transformation by chemical
carcinogens, DNA or RNA viruses (Cooper et al., 1985;
Hendricks and Weintraub, 1984; Lin et al., 1985; Matsumura
et al., 1983). For example, a rat embryo fibroblast cell line
transformed with the DNA transforming virus adenovirus type-
5 fail to express any detectable TM-1 (Matsumura et al., 1983).
These cells have a pronounced spindle morphology and contain
relatively few actin filaments compared to the parent cell line.
Similarly NRK 1569 cells, derived from a well spread normal
rat kidney cell line (NRK1570) that have been transformed byoinjection. Expressed TM isoforms were fluorescently labeled with
d TM-1 produced in insect cells. (B) TM-6/10 produced in bacteria.
xture of a and b isoforms. Although microfilament labeling appeared
 skeletal muscle, those isoforms which readily bound F-actin, best
, these photographs were all taken 12-14 hours after injection. TM-1
 TM-7Cla failed to incorporate into the microfilaments of injected cells
3263Alternatively spliced exons of the b tropomyosin genethe v-ras containing Kirsten RNA virus grow as quite rounded
cells, loosely attached to the substrate. These cells do not
produce detectable TM-2 or TM-3 proteins (Matsumura et al.,
1983). Recently, it has been reported that the 3¢ untranslated
region of a tropomyosin mRNA may suppress transformation
by an as yet unidentified mechanism (Rastinejad et al., 1993). 
Caldesmon promotes TM-1 binding to F-actin
Nonmuscle 83 kDa caldesmon (CaD) is known to have a
periodic localization along microfilaments (Yamashiro-
Matsumura and Matsumura, 1988) and binds tropomyosin
through residues in its C-terminal half (Watson et al., 1990).
Lin and co-workers have recently shown that forced expression
of the carboxy-terminal half of nonmuscle CaD can stabilize
TM association and enhance microfilament stability in CHO
cells (Warren et al., 1994). To investigate the effect of
caldesmon on the association of b TM isoforms with actin
filaments, the full length bacterially expressed 83 kDa CaD
protein was included in the TM:F-actin association assays. As
we have shown in Fig. 7, caldesmon has a strong positive effect
on the binding of TM-1 to F-actin. This isoform utilizes the
alternatively spliced exons 6 (internal) and 11 (carboxy-
terminal). The binding of the isoform b Sk TM and chimera
TM-6/10 was affected in a minimal but positive manner whenFig. 11. Diagram of the association of TM-1, TM-2, and caldesmon
(CAD) with F-actin. (A) A diagram of the association of TM-1, TM-
2 and caldesmon that is consistent with the results is shown; TM-1 is
indicated in white and TM-2 in black. TM-2 binds along most of the
F-actin filament, but positions are also occupied by TM-1, which is
stabilized by the overlaps with TM-2 and the presence of nonmuscle
caldesmon (nonphosphorylated). (B) Events which require filament
reorganization may proceed by first removing caldesmon (in this
case by phosphorylation). TM-1 association is weakened and slowly
becomes detached. (C) The actin filament is then naked and









100 Åcaldesmon was present, while little or no effect was seen with
the expressed chimera TM-7/11. The expressed, truncated
proteins TM-6Cla and TM-7Cla showed virtually no increase
in actin binding when caldesmon was present. Hence, among
these TM proteins, there is a requirement for the exons 6 and
11 to achieve the maximal enhancement of TM binding by 83
kDa caldesmon.
The enhancement of TM-1 binding to F-actin in the presence
of 83 kDa CaD agrees well with the reports of 140 kDa smooth
muscle caldesmon enhancing the binding of smooth muscle
TM or recombinant b smooth muscle TM (identical to TM-1)
to actin filaments (Novy et al., 1993a). The 83 kDa caldesmon
has not been as extensively studied as the smooth muscle coun-
terpart, however, similar properties include the binding of TM
and calmodulin, as well as filamentous actin and the inhibition
of actomyosin ATPase. The interaction of 83 kDa caldesmon
with F-actin has been shown to be regulated by Ca2+/calmod-
ulin or phosphorylation by the mitotically active cdc2 kinase
(Yamashiro et al., 1990). The association of 83 kDa caldesmon
with the cytoskeleton is known to be inhibited by elevated
Ca2+/calmodulin levels, and increases in levels of intracellular
Ca2+ would be expected to allow activation of actomyosin
ATPase activity and increases in cellular motile activities.
Similarly, the release of CaD (see Fig. 11) followed by a
weakening of the TM-1:microfilament association, may allow
severing proteins such as gelsolin, to cleave the unprotected
actin filaments efficiently. As an example, in a motile fibrob-
last that is undergoing changes in morphology, local microfil-
ament reorganization involving TMs and CaD could be respon-
sive to Ca2+ levels prompted from intracellular stores or
membrane fluxes by receptor-based mechanisms. The sensi-
tivity of CaD to cdc2 kinase phosphorylation may promote the
pronounced alterations of the cytoskeleton that must occur
prior to mitosis. As the cell then progresses through the cell
cycle, the dramatic changes that occur throughout the
cytoskeleton in readiness for mitosis could be controlled by
phosphorylation events on CaD and other components of the
cytoskeleton.
Fluorescently taggged isoforms microinjected into
cells do not show differential subcellular
localization 
The incorporation of microinjected b Sk TM and TM-6/10
produced in bacteria was rapid and extensive throughout the
fibroblast cytoskeleton as was the TM purified from rabbit
muscle (Figs 9 and 10). The bacterially produced TM-1 failed
to incorporate, but the acetylated TM-1 from the insect cell
expression system was found in the characteristic striations
along stress fibers. When the TM localization was compared
with fluorescein-phalloidin staining, all actin filaments
appeared to have the introduced TMs bound along their length.
No difference could be discerned between the localization of
these microinjected TMs. It would be intriguing to know
whether the periodic CaD localization previously reported
(Bretscher and Lynch, 1985; Yamashiro et al., 1990) correlates
with the periodic staining of TM-1. 
While microinjection of labeled TM protein into fibroblasts
has not yet shown a difference in isoform localization, anti-
bodies that can distinguish between certain isoforms have been
used to show such differences in 293 cells (Lin et al., 1988) or
the more highly differentiated porcine intestinal epithelial
3264 M. F. Pittenger, A. Kistler and D. M. Helfmancells, LL-CPK1 (C. Temm, D. M. Helfman, and B. Jockusch,
unpublished). Furthermore, tropomyosin isoform expression
has been shown to respond to altered actin isoform expression
(Schevzov et al., 1993) and actin isoforms have been shown to
sort in microvascular pericytes (DeNofrio et al., 1989). By
microinjecting protein isoforms, it is possible that a mechanism
for isoform sorting that occurs at the level of mRNA has been
circumvented. This is a testable hypothesis and future experi-
ments will address some of these questions. 
The expression of the alternatively spliced TMs is found to
vary in a tissue specific manner that is conserved across
species, suggesting differences in their functions. There are
regions of TM that are encoded by conserved exons and those
that are encoded by alternatively spliced exons. The complex-
ity of TM expression is unlikely to be the result of redundancy
as a wealth of in vitro experiments has shown TM isoforms to
vary in their properties towards actin and actin binding or
severing proteins. Future work should allow a better apprecia-
tion of the cellular functions that tropomyosin isoforms facili-
tates and how their interactions with other proteins of the
microfilament system effect its dynamics.
The plasmid to produce recombinant caldesmon was kindly
provided by F. Matsumura and S. Yamashiro. Special thanks to Phil
Renna and Jim Duffy for art work. DMH is support by a grant from
the National Cancer Institute (CA58607) and is an Established Inves-
tigator of the American Heart Association.
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